12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.
You may also be interested in...
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
In this week's podcast edition of Five Must-Know Things: senior level changes at Lilly; mRNA COVID vaccines and booster shots; GSK and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.